论文部分内容阅读
自从Lawrence最初提出转移因子的作用以来的30余年中,先后已召开了4次国际TF学术会议,推动了这方面研究的进展。七十年代中期开始,用正常人血液、扁桃体、脾脏制备的TF在我国临床上应用证明,对某些病毒感染,免疫缺陷,免疫失调及人体对放、化疗的副反应等的治疗取得了较满意的效果而受到欢迎,但关于TF的性质与作用机理至今还不明确,所用细胞来源的限制,至今尚未解决。针对上述问题,
In the more than 30 years since Lawrence first proposed the role of the transfer factor, four international TF academic conferences have been held successively to promote the progress of this research. Since the mid-1970s, TF prepared with normal human blood, tonsils, and spleen has been clinically proven in China, and has achieved better results in the treatment of certain viral infections, immunodeficiency, immunological disorders, and side reactions to radiotherapy and chemotherapy. Satisfactory results have been welcomed, but the nature and mechanism of action of TF have not yet been clarified, and the limitations of cell sources used have not yet been resolved. Regarding the issue above,